Symposium for Medical Cannabis 2022

Invest in denmark are co-hosting the 3rd annual symposium on medical cannabis

The Danish and European medical cannabis industry is at a key inflection point. More European countries are opening up to medical cannabis, both as a new treatment option for patients but also as an emerging industry that creates high-quality jobs, drives exports, and attracts investment.

The shape of these industries is still unknown, with no common European model to set the scope of development. National regulations and priorities continue to set the framework, with each country pursuing different priorities and markets.

After an experimental pilot program from 2018 to 2021, the Danish government established a permanent framework for medical cannabis production that started in 2022. A permanent framework reduces risk for investment while also opening new opportunities for the development of new plant genetics, API production, and manufacturing final products.

The Danish medical cannabis industry is based on a medical cannabis model, with an open-ended licensing regime based on high quality but no limits to the scale of production. This model has made Denmark into a leading centre for medical cannabis production and aligns with the broader Life Sciences industry, which accounts for over 22 percent of Denmark’s exports.

In the broader Life Sciences industry, Denmark is a leading nation for R&D expenditure, clinical research, and drug development. This platform provides a solid basis for the medical cannabis industry to draw on the strengths of the Danish Life Sciences industry, but it requires partnerships, collaboration, and a commitment to longer-term investments in knowledge and research.

This is theme of the 3rd Annual Symposium on Medical Cannabis, hosted by the Danish Technological Institute and Invest in Denmark: Connecting to the Life Sciences. The theme of this year’s Symposium on Medical Cannabis relates to the place of medical cannabis within the broader Life Sciences industry, identifying areas within the medical cannabis industry where connections with the broader Life Science industry help drive development.

As has been the case every year, the Symposium is based on understanding the value chain “From Plant to Patient” and involves creating links between the various stakeholders that are involved in the dynamic industry.

Panel Session 1: Intellectual Property in Medical Cannabis
Panel Session 2: Advances in cultivation technologies
Panel Session 3: Product Development
Panel Session 4: Real World Evidence (RWE) in Medical Cannabis
Panel Session 5: Denmark as a platform for evidence

Light food/drinks and networking afterwards